

# Biomarkers: Market Research Report



Phone: +44 20 8123 2220  
Fax: +44 207 900 3970  
office@marketpublishers.com  
<http://marketpublishers.com>

## Biomarkers: Market Research Report

Date:	August 1, 2011
Pages:	1305
Price:	US\$ 4,800.00
ID:	B0ACF7C2E29EN

This report analyzes the worldwide markets for Biomarkers in US\$ Million by the following Technologies and Services: Technologies - Emerging Biomarker Technologies (Imaging biomarkers, Proteomics, Transcriptomics, & Bioinformatics), Conventional Biomarker Technologies - (Immunodiagnosics, & Molecular Diagnostics), and Others; Services - Clinical Biomarker Services, Specimen Preparation, and Bioinformatics and Others (miRNA Analysis and Others).

The total market is also analyzed by the following Application Areas: Biomarker Discovery, Clinical Drug Development, and Diagnostics Techniques (Molecular).

Key Therapeutic Areas also analyzed in the report include Oncology, Cardiology, CNS, and Others.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2008 through 2017.

The report profiles 204 companies including many key and niche players such as Abbott Laboratories, Affymetrix, Inc., Agilent Technologies, Inc., Alexion Pharmaceuticals, Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMérieux, Bruker Corporation, Caprion Proteomics, Inc., Clariant Inc., Compugen, Ltd., Correlologic Systems, Inc., DiagnoCure, Inc., Epigenomics AG, GE Healthcare, Gene Logic, Genedata AG, Gen-Probe Inc., GlaxoSmithKline Plc, Hitachi Medical Corporation, Illumina, Inc., LabCorp., Life Technologies Corporation, Merck & Co. Inc., Metabolon, Inc., Myriad Genetics, Inc., Novartis International AG, Panacea Laboratories, Pfizer, Inc., Philips Healthcare, QIAGEN NV, Quest Diagnostic, Inc., Quest Diagnostics Company, Roche Diagnostics Corp., Rubicon Genomics, Inc., Rules-Based Medicine, Inc., and Siemens Healthcare Diagnostics, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

### Table of Content

#### 1.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definition and Scope of Study
- Definitions
- Biomarker Technologies
- Emerging Biomarker Technologies
- Proteomics
- Transcriptomics

Imaging biomarkers  
Bioinformatics  
Conventional Biomarker Technologies  
Molecular Diagnostics  
Immunodiagnostics  
Other Biomarker Technologies  
Metabolite and Enzyme Assays  
Reagents  
Biomarker Services  
Clinical Biomarker Services  
Biomarker Testing  
Assay Development and Production  
Antibody Development  
Specimen Preparation  
Bioinformatics and Others

## 2.INDUSTRY OVERVIEW

Global Biomarkers Market Surges in the Backdrop of Widening Medical Scope and Applications  
Factors Engendering Positive Vibes  
Factors Engendering Positive Influence on the Biomarkers Market: A Summary  
Biomarkers: A Regional Perspective  
US Spearheads the Global Biomarkers Market  
US and Japan Take Lead on the Patent Front

**Table 1.** Dominance of US in the Global Biomarker Patent Filings (includes corresponding Graph/Chart)

**Table 2.** Leading Players in the Biomarkers Space by Number of Patent Filings (includes corresponding Graph/Chart)

**Table 3.** Number of Biomarker Patents Published and Filed: 2003-2007 (includes corresponding Graph/Chart)

Asia-Pacific: The Fastest Growing Biomarker Market  
Supportive Governments and Regulatory Bodies to Fuel Growth  
Increasing Collaborations Among Regulators and Companies Augur Well for Biomarkers  
Player Strategies: An Insight

**Table 4.** Growing Number of Biomarker Deals (includes corresponding Graph/Chart)

**Table 5.** Competitive Strategy Mix in the Global Oncology Biomarkers Market (includes corresponding Graph/Chart)

Pharma and Biomarker Developer Tie-Ups to Raise Drug Development Productivity

## 3.MARKET OUTLOOK

Biomarkers: Evolving Scope and Applications  
Technological Advancements – A Boon for Biomarker Discovery  
Evolving Role of Biomarkers in Drug Development  
Companion Biomarkers  
Biomarkers Play Invaluable Role in Oncology and Cardiovascular Disease Diagnosis  
Personalized Medicine- Revolutionizing the Medical Treatment

Biomarker-Led Drug Discovery – A Profitable Investment  
Technological Trends  
Proteins Gain Upper Hand in Biomarkers  
Mass Spectrometry – A Promising Technology in Molecular Medicine  
Market Restraints  
Challenges in Biomarker Validation – A Major Growth Retardant  
The Road Ahead  
Biomarkers to Witness Significant Growth in Therapeutic and Diagnostic Arenas  
Efficiency Improvements Must for Realizing Cost-Effective Biomarker Testing

#### **4. BIOMARKER TECHNOLOGIES AND SERVICES: AN OVERVIEW**

Biomarker – Definition & Introduction

#### **BIOMARKER TECHNOLOGIES**

##### **EMERGING BIOMARKER TECHNOLOGIES**

Proteomics  
Growth Drivers and Market Trends  
Efficiency Gains in Drug Discovery Drive Growth in Proteomics  
Proteomics Witness Increased Focus on Targeted Approach  
Mass Spectrometry – Shifts in Focus to Proteomics Helps Biomarker Development  
Mass Spectrometry Expands Scope of Protein Biomarker Applications  
Transcriptomics  
Transcriptomics – Assisting in Identification of Biomarkers  
Imaging Biomarkers: Disease Diagnosis, the Non-Invasive way  
Types of Imaging Biomarkers – An Overview  
Market Trends  
Molecular Imaging - Gaining Importance in Drug Discovery and Development  
Use of Molecular Imaging in Clinical Trials for Drug Development  
Bioinformatics

##### **CONVENTIONAL BIOMARKER TECHNOLOGIES**

Molecular Diagnostics  
Immunodiagnostics  
Market Trends  
Growth in Use of Molecular Diagnostics to Propel Biomarker Growth  
Demand for Novel Biomarkers Persists in Immunodiagnostics  
Immunoassays Plagued with Standardization Issues

##### **OTHER BIOMARKER TECHNOLOGIES**

Metabolite and Enzyme Assays  
Reagents  
Market Trends  
Microarrays Surge Biomarker Identification  
Metabolomics Gain Rapid Foothold in Drug Discovery

##### **BIOMARKER SERVICES**

Expanding Capabilities Drive Large-Scale Adoption  
Clinical Biomarker Services  
Biomarker Testing

Assay Development and Production  
Antibody Development  
Specimen Preparation  
Bioinformatics and Other Biomarker Services  
Bioinformatics Gain Prominence  
miRNA Analysis  
Microarray Services Witness Increasing Investments

## 5. BIOMARKERS MARKET BY APPLICATION

Role of Biomarkers in Drug Discovery and Development  
Role of Biomarkers in Clinical Research and Patient Management  
Major Benefits of Biomarkers in Clinical Development  
Major Benefits of Biomarkers in Medicine  
Multifarious Applications of Biomarkers  
New Applications Come to the Fore  
Application of Biomarkers in Drug Development  
Herceptin and Vilazodone –References for Success of Biomarker Based Approach  
Increasing Role of Biomarkers in Modern Drug R&D  
Translational Medicine Biomarkers Revolutionizing Drug Development Process  
Outsourcing - Opportunities Galore  
CROs in a Dilemma Over Investments in Biomarker Analysis Services  
Lower Productivity of Traditional Drug Discovery Approach Calls for New Methods  
Blockbuster Model Versus Personalized Medication Model  
Workflow Standardization – Key to Success of Biomarkers in Drug Development

## 6. BIOMARKERS BY THERAPEUTIC AREA

Current & Future Analysis

### ONCOLOGY

Factors Driving Oncology Biomarkers' Growth  
US Remains at the Forefront of Cancer Biomarker Patent Filings

**Table 6.** Regional Split in the Global Cancer Biomarker Patent Filings: 2009 (includes corresponding Graph/Chart)

**Table 7.** Leading Players in Cancer Biomarkers by Number of Patent Filings: 2004-2009

Global Oncology Diagnostics and Drug Discovery Biomarkers Market

**Table 8.** World Recent Past, Current and Future Analysis for Oncology Biomarkers Market by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 9.** World 10-Year Perspective for Oncology Biomarkers Market by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 10.** Global Cancer Biomarkers Diagnostics (Molecular) Market by Company (2009): Market Share Breakdown of Revenues for Roche, Gen-Probe, Myriad, Abbott, QIAGEN and Others (includes

corresponding Graph/Chart)

Evolution of Oncology Biomarkers  
Available and Pipeline Biomarkers in Various Cancers  
Breast Cancer Dominates Cancer Biomarkers Pipeline

**Table 11.** Global Cancer Biomarkers Pipeline by Indication (2010): Percentage Share Breakdown for Breast Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, and Others (includes corresponding Graph/Chart)

**Table 12.** Global Oncology Biomarkers Market: Percentage Breakdown of Patent Filings by Oncology Area (2007)

Breast Cancer Market Awaits New Specific Biomarkers  
Oncology Biomarker Diagnostic Techniques

**Table 13.** Leading Cancer Biomarker Diagnostic Technologies (2009): Percentage Share of Value Sales for Gene-based Markers, Proteomics, DNA Microarrays, Immunological Markers and IHC Tests, and Others (includes corresponding Graph/Chart)

Current Trends in Cancer Biomarkers  
Validation Techniques Take Center Stage  
Early-Stage Use of Biomarkers High in Oncology  
Proteomics Ahead of Genomic Biomarkers in Functionality  
Pharmacogenomics and IHC Tests Inch Ahead in Cancer Biomarker Diagnostics  
Faster Diagnosis Benefits DNA Microarray Technology  
Other Tests Lose Market Share  
Companion Biomarkers in Oncology

## **CARDIOLOGY**

Market Trends  
Increasing Health Burden Drives Research Efforts  
Gene Expression Analysis Delivers Novel Therapeutic Approaches  
High-Performance Techniques Drive Biomarker Discovery in Cardiology  
Effective Phenotyping Takes Precedence for Successful Genotyping Studies  
Role of Linkage Analysis in Cardiovascular Biomarker Identification  
Biomarkers of ACS  
Biomarkers – A Promising Diagnostic Tool for ACS  
Biomarker Discovery in Cardiovascular Diseases to Undergo Significant Changes  
Major Cardiovascular Diagnostic Biomarkers – A Focus on Biomarkers for ACS  
Creatine Kinase-Myocardial Band  
Natriuretic Peptides  
Cardiac Troponin  
Myoglobin  
New Diagnostic Biomarkers for ACS on the Anvil  
Genomic Biomarkers for Detecting Cardiovascular Diseases  
Growing Demand for Stroke Biomarkers  
Rising Incidence of the Disease – A Major Driver for Stroke Biomarkers

## **CENTRAL NERVOUS SYSTEM (CNS)**

Lower Commercial Availability Restricts Market Share

Research Efforts Remain Confined to Specific Areas  
High Cost of Treatment Shadows Biomarkers' Short-Treatment Benefits  
Research Methodology in CNS Biomarkers  
Alliances – A Key Aspect to the Development of CNS Biomarkers  
Biomarkers in Select CNS Diseases  
Alzheimer's Disease  
Parkinson's Disease Biomarkers - Crucial for Neuroprotectants' Effectiveness  
Schizophrenia: An Unexploited Segment

## **OTHER THERAPEUTIC AREAS**

Inflammatory and Autoimmune Disorders  
Biomarkers offer Efficient Diagnosis and Treatment  
Rheumatology

## **7. AN OVERVIEW OF SELECT BIOMARKERS**

HER2/neu/ ErbB2 Gene  
HER2 and its Association with Cancer  
Target Drugs for HER2  
Hepsin Biomarkers  
Early Prostate Cancer Antigen-2

## **MMP-3**

ImmunoCyt™/uCyt+™  
AmpliChip CYP450 Test  
The OncoVue® Breast Cancer Risk Test  
Oncotype DX® Test  
Oncotype DX Colon Cancer Assay  
MammaPrint  
Theros CancerTYPE ID  
PgxPredict:CLOZAPINE– Test for Qualifying Patients to Use Clozapine  
The Pathwork Tissue of Origin Test  
PROGENSA PCA3 Assay  
Epi proColon® Early Detection Assay  
OVA1® Test  
Bcr-abl Fusion Protein

## **HLA-B**

Mammostrat®  
Ipsogen MapQuant Dx™ Genomic Grade  
CA1-18 Enzyme Immunoassay (EIA)  
Anti-L523S Antibody

## **8. PRODUCT INTRODUCTIONS IN THE BIOMARKERS SPACE**

RBM Unveils OncologyMAP® Panel of 101 Quantitative Biomarker Tests  
Avantra Introduces New BioChip Immunoassay Biomarker Workstation  
Clariant Introduces Mammostrat Test  
Biomagnetics Diagnostics Identifies Second Biomarker for Tuberculosis Assay  
Epistem Introduces Novel Ex Vivo Plucked Hair Biomarker Assay  
Crescendo Bioscience Launches New Multi Biomarker Blood Test  
Alere International Launches New Triage® NT-proBNP Test

Agilent Technologies Launches New SureSelect Kinome Target Enrichment Kit  
Roche Diagnostics to Launch New STAT Immunoassays  
Gentel Biosciences Launches New Human Profiling Kits  
QIAGEN Introduces QIASymphony RGQ System  
Almac Introduces Biomarkers for Biopharmaceutical Industry  
i-Path Introduces TMA Toolbox  
Abbott Introduces ARCHITECTPLUS Systems  
Affymetrix Introduces QuantiGene® ViewRNA Assayformats  
ARUP Laboratories Introduces New Test for Colorectal Cancer Detection  
Warnex Launches Blood Testing Service for Colorectal Cancer in Canada  
Agilent Technologies Launches mAb-Glyco-Chip  
synlab Launches Septin9 Testing in Germany  
IDBS Introduces New Biomarker Discovery and Validation Solution  
Quest Diagnostics Introduces Blood Test for Detecting Colorectal Cancer  
Clariant Introduces Biomarker Panel for NSCLC Classification  
Institute of Microelectronics and Agency for Science, Technology and Research Launch Rapid Cardiac Biomarker Test  
Rules-Based Medicine Unveils CardiovascularMAP™ for CVD Treatment  
Thermo Fisher Introduces New Copeptin Assay  
Psynova Neurotech and RBM Identify New Biomarkers for Schizophrenia  
Genedata Unveils Genedata Expressionist® 5.3  
Arrayit Introduces Biomarker Discovery Service  
Invitrogen Introduces Biomarker Tool for Kidney Function Research  
Abbott Introduces ARCHITECT® c4000®  
Epigenomics Rolls Out Epi proColon Range in Europe  
Genedata Introduces Expressionist 5.2 for Identifying MS-based Biomarker  
VisEn Unveils FAST – A Novel Imaging Platform  
Millipore and CXR Biosciences Unveils ToxReporter™  
Rules-Based Medicine Unveils Human Kidney Multi-Analyte Profile  
MDS and Applied Biosystems Launch AB SCIEX TOF/TOF™ 5800 System  
Genetic Biomarkers for Chronic Kidney Disease  
Bruker Launches Advanced MALDI-TOF/TOF Mass Spectrometer  
Satoris Introduces three Novel Blood Tests  
GE Healthcare Launches Discovery™ MR450  
GE Healthcare in Partnership with Varian Launches Discovery MR901 (US)  
Applied Biosystems and MDS Analytical Launches Novel New Mass Spectrometry Tools  
Rules-Based Medicine Commercializes Rat Kidney MAP Biomarker Panel  
Thomson Reuters Introduces BIOMARKERcenter  
Gentel® Biosciences Introduces SilverQuant™ GlycoBiomarker Array Kit  
BioMarker Pharmaceuticals Introduces Gene Essence™ DNA Test  
mtm laboratories Introduces Cervatec™ Assay  
Decision Biomarkers Introduces AVANTRA Biomarker Workstation  
Aureon Introduces Prostate Px® to Predict Progression and Recurrence of Prostrate cancer  
VisEn Introduces a Novel Imaging Agent

## **9. BIOMARKERS M&A ACTIVITY**

QIAGEN to Take Over Stake in Alacris Theranostics  
Transgenomic Acquires Certain Businesses of Clinical Data  
Caliper Life Sciences Acquires Cambridge Research & Instrumentation  
Biosystems International and MicroBioChips Merge  
Axela Takes Over Xceed Molecular  
Accelrys Merges with Symyx Technologies  
Caprion Proteomics Acquires PPD's Biomarker Division  
QIAGEN Takes Over SABiosciences



Thermo Fisher Scientific Takes Over Brahm's  
QIAGEN Takes Over DxS  
ICON Takes Over Veeda Laboratories  
ID Business Solutions Takes Over InforSense  
Clinical Data Acquires Avalon Pharmaceuticals  
Genetix Takes Over SlidePath  
Oxford Gene Technology Takes Over Sense Proteomic  
Tethys Bioscience Takes Over Lipomics Technologies  
QPS LLC Acquires Bio-Kinetic Clinical Applications  
AltheaDx Rolls Out Affymetrix DMET Genotyping Microarray Service

## **10. COLLABORATIONS AND AGREEMENTS**

Proteome Sciences Bags Contract from Eisai  
MDxHealth to Ink Partnership Agreement with Pfizer, Cancer Research Technology and Newcastle University  
Takeda and Zinfandel Enter into License Agreement for AD Biomarker  
Pacific Biomarkers Forges Research Deals with Two Multinational Firms  
SMA Foundation and RBM Partner to Develop Panel of SMA Biomarker  
Epigenomics Enters into Collaboration with QIAGEN to Develop Colorectal Cancer Blood Tests  
Vermillion Inks Agreement with Quest to Launch OVA1® in India  
DiaGenic and Pfizer Team Up for Identifying Biomarkers for AD  
Prometheus Signs Agreement with The Regents of the University of California  
Aushon BioSystems Enters into Partnership with LightArray Biotech  
GE Healthcare Collaborates with Johnson & Johnson  
ICON Enters into Strategic Alliance with Proteome Sciences  
Epigenomics Inks Distribution Agreement with DATEKS  
Epigenomics Inks Distribution Agreement with Pronto Diagnostics  
Thermo Fisher Collaborates with Proteome Sciences  
Diaceutics Teams Up with London Genetics to Develop Software Decision Tools  
OncoMethylome Enters Into Agreement with GlaxoSmithKline Biologicals  
SureGene Enters into Research Collaboration with Medco Research Institute  
Ariadne Inks Agreement with Roswell Park Cancer Institute and Cellecta  
SDIX Enters into Multi-Year Collaboration with Banyan Biomarkers  
Roche Acquires Co-exclusive License from QIAGEN  
Metabolon Collaborates with Colgate-Palmolive for Periodontal Disease Biomarkers Identification  
Toscana Biomarkers and Regione Toscana Enter into Grant Agreement  
ACC and Roche Diagnostics Initiate Collaboration  
Epigenomics Inks Distribution Agreement with DPC LEBANON  
Duke Enters into Joint Venture with LabCorp for Biomarker Commercialization  
HDC and SPM Enter Into Agreement with Quest Diagnostics  
Toscana Biomarkers Collaborates with QuantiScientifics  
Intrinsic Bioprobes Licenses New Biomarkers to Ortho-Clinical Diagnostics  
Shimadzu Allies with Nonlinear Dynamics and Ceres Nanosciences  
PAREXEL Enters into Partnership with Proteome Sciences  
Biocartis Inks Agreement with Royal Philips Electronics  
QIAGEN Signs Agreement with Wuxi AppTec  
SDIX Enters into Collaboration with Fred Hutchinson Cancer Research Center  
Siemens Teams UP with EDPL to Institute Cyclotron Facility in India  
ALS TDI Concluded First Phase of Collaboration with Applied Proteomics  
Psynova Neurotech Teams Up with Roche for Schizophrenia Treatment Development  
Minerva Biotechnologies Licenses Exclusive Marketing Rights to Clariant  
Rules-Based Medicine Signs Biomarker-Driven Agreement with Covance  
BG Medicine and Abbott Ink Agreement for galectin-3 Biomarker  
Epigenomics and ARUP Ink Non-Exclusive Agreement

Biosystems International Signs Licensing Agreement with Lohocla Research  
Axela Signs Agreements with Micromedics and Proteome Sciences  
Moffitt Cancer Center and Frantz BioMarkers Enter into Licensing Agreement  
Fujirebio Diagnostics Signs Agreement with BD for Oncology Diagnostic Assays  
Quest Diagnostics Bags Prostrate Cancer Test License from Epigenomics  
Genedata Extends Collaboration Agreement with Roche  
BioTheranostics Inks Commercialization Agreement with Lab 21 for THEROS CancerTYPE ID  
Researchers Utilizes AB Sciex Qtrap 5500 System to Detect Biomarkers  
Fujirebio Inks Agreement with Abbott to Develop Ovarian Cancer Test  
Caprion and Applied Bioystems Partners to Accelerate Validation and Verification of Protein Biomarker  
Sysmex Inks Research Partnership Deal with Epigenomics  
Pharsight Inks Agreement with InforSense  
AstraZeneca and Washington University Team Up to Develop Novel Methods for Alzheimer's Disease  
Diagnosis and Treatment

## **11. OTHER CORPORATE INITIATIVES IN BIOMARKERS SPACE**

Genedata Installs Genedata Expressionist® Refiner MS at Victoria DPI  
Genedata Deploys Genedata Expressionist® at Hospital for Sick Children  
Covance Establishes New Unit for Discovery and Translation Services  
The University of Liege Spins-off Targetome Business  
PMDA Accepts Biomarker Panel of Critical Path's  
Clariant Obtains UK Patents for the TLE3 Biomarker  
Agilent Supplies Mass Spectrometry Devices to Stemina Biomarker Discovery  
Pacific Biomarkers to Launch New Logo, Marketing and Branding Initiatives  
SMA Foundation Completes Biomarker Study  
Genedata Offers Genedata Expressionist® to RIKEN  
Chronix Biomedical Strengthens Biomarker Development Capabilities  
Aureon Changes Name of Colorectal Cancer Prognostic Test  
Satoris Gains Global Distribution Rights to RBM's DiscoveryMAP™ Panel  
Teva Pharmaceutical Industries to Use Biomarkers of Compugen  
Genedata Provides Genedata Expressionist® System to Asubio Pharma  
InforSense Aids Biomarker Discovery Process by Celera  
Xennex Provides Satoris with Access to GeneCards®  
IME Developed Silicon-Based Testing System for Cardiac Biomarkers

## **12. FOCUS ON SELECT GLOBAL PLAYERS**

Abbott Laboratories (US)  
Affymetrix, Inc. (US)  
Agilent Technologies, Inc. (US)  
Alexion Pharmaceuticals, Inc. (USA)  
Beckman Coulter, Inc. (US)  
Becton, Dickinson and Company (US)  
Bio-Rad Laboratories, Inc. (US)  
BioMerieux (France)  
Bruker Corporation (US)  
Caprion Proteomics, Inc. (Canada)  
Clariant Inc. (US)  
Compugen, Ltd. (Israel)  
Correlogic Systems, Inc. (US)  
DiagnoCure, Inc. (Canada)  
Epigenomics AG (Germany)  
GE Healthcare (UK)  
Gene Logic (US)

Genedata AG (Switzerland)  
Gen-Probe Inc. (US)  
GlaxoSmithKline Plc. (UK)  
Hitachi Medical Corporation (Japan)  
Illumina, Inc. (US)  
LabCorp. (US)  
Life Technologies Corporation (US)  
Merck & Co., Inc. (US)  
Metabolon, Inc. (US)  
Myriad Genetics, Inc. (US)  
Novartis International AG (Switzerland)  
Panacea Laboratories (US)  
Pfizer, Inc. (US)  
Philips Healthcare (Netherlands)  
QIAGEN NV (The Netherlands)  
Quest Diagnostic, Inc. (US)  
Roche Diagnostics Corp. (US)  
Rubicon Genomics, Inc. (US)  
Rules-Based Medicine, Inc. (US)  
Siemens Healthcare Diagnostics, Inc. (US)

### 13. GLOBAL MARKET PERSPECTIVE

**Table 14.** World Recent Past, Current and Future Analysis for Biomarkers by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 15.** World 10-Year Perspective for Biomarkers by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 16.** World Recent Past, Current and Future Analysis for Biomarker Technologies by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 17.** World 10-Year Perspective for Biomarker Technologies by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 18.** World Recent Past, Current and Future Analysis for Biomarker Technologies by Segment – Emerging Biomarker Technologies, Conventional Biomarker Technologies, and Other Biomarker Technologies Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 19.** World 10-Year Perspective for Biomarker Technologies by Segment – Percentage Breakdown of Dollar Sales for Emerging Biomarker Technologies, Conventional Biomarker Technologies, and Other Biomarker Technologies Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 20.** World Recent Past, Current and Future Analysis for Emerging Biomarker Technologies by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 21.** World 10-Year Perspective for Emerging Biomarker Technologies by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 22.** World Recent Past, Current and Future Analysis for Emerging Biomarker Technologies by Segment – Imaging biomarkers, Proteomics, Transcriptomics, and Bioinformatics Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 23.** World 10-Year Perspective for Emerging Biomarker Technologies by Segment – Percentage Breakdown of Dollar Sales for Imaging biomarkers, Proteomics, Transcriptomics, and Bioinformatics Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 24.** World Recent Past, Current and Future Analysis for Imaging Biomarkers by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 25.** World 10-Year Perspective for Imaging Biomarkers by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 26.** World Recent Past, Current and Future Analysis for Proteomics in Biomarkers Market by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 27.** World 10-Year Perspective for Proteomics in Biomarker Market by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 28.** World Recent Past, Current and Future Analysis for Transcriptomics in Biomarkers Market by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 29.** World 10-Year Perspective for Transcriptomics in Biomarkers Market by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 30.** World Recent Past, Current and Future Analysis for Bioinformatics in Biomarkers Market by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 31.** World 10-Year Perspective for Bioinformatics in Biomarkers Market by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 32.** World Recent Past, Current and Future Analysis for Conventional Biomarker Technologies by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 33.** World 10-Year Perspective for Conventional Biomarker Technologies by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World

Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 34.** World Recent Past, Current and Future Analysis for Conventional Biomarker Technologies by Segment – Immunodiagnostics and Molecular Diagnostics Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 35.** World 10-Year Perspective for Conventional Biomarker Technologies by Segment – Percentage Breakdown of Dollar Sales for Immunodiagnostics and Molecular Diagnostics Markets for Years 2008, 2011, and 2017 (includes corresponding Graph/Chart)

**Table 36.** World Recent Past, Current and Future Analysis for Immunodiagnostics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 37.** World 10-Year Perspective for Immunodiagnostics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 38.** World Recent Past, Current and Future Analysis for Molecular Diagnostics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 39.** World 10-Year Perspective for Molecular Diagnostics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 40.** World Recent Past, Current and Future Analysis for Other Biomarker Technologies by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 41.** World 10-Year Perspective for Other Biomarker Technologie by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 42.** World Recent Past, Current and Future Analysis for Biomarker Services by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 43.** World 10-Year Perspective for Biomarker Services by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 44.** World Recent Past, Current and Future Analysis for Biomarker Services by Segment– Clinical Biomarker Services, Specimen Preparation, and Other Biomarker Services Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 45.** World 10-Year Perspective for Biomarker Services by Segment – Percentage Breakdown of Dollar Sales for Clinical Biomarker Services, Specimen Preparation, and Other Biomarker Services Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 46.** World Recent Past, Current and Future Analysis for Clinical Biomarker Services by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed



with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 47.** World 10-Year Perspective for Clinical Biomarker Services by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 48.** World Recent Past, Current and Future Analysis for Specimen Preparation by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 49.** World 10-Year Perspective for Specimen Preparation by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 50.** World Recent Past, Current and Future Analysis for Other Biomarker Services by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 51.** World 10-Year Perspective for Other Biomarker Services by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 52.** World Recent Past, Current and Future Analysis for Biomarkers by Application – Biomarker Discovery, Clinical Drug Development, and Diagnostics Techniques (Molecular) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 53.** World 10-Year Perspective for Biomarkers by Application – Percentage Breakdown of Dollar Sales for Biomarker Discovery, Clinical Drug Development, and Diagnostics Techniques (Molecular) Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 54.** World Recent Past, Current and Future Analysis for Biomarkers by Therapeutic Area – Cancer Biomarkers, Cardiology Biomarkers, CNS Biomarkers, and Other Therapeutic Biomarker Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 55.** World 10-Year Perspective for Biomarkers by Therapeutic Area – Percentage Breakdown of Dollar Sales for Cancer Biomarkers, Cardiology Biomarkers, CNS Biomarkers, and Other Therapeutic Biomarker Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

## 14. THE UNITED STATES

### A. Market Analysis

Current & Future Analysis

Companies Wake Up to the Growing Need for Effective Biomarkers

Biomarker Regulations in the US

Product Launches

Strategic Corporate Developments

Focus on Select Major Players

### B. Market Analytics

**Table 56.** The US Recent Past, Current and Future Analysis for Biomarkers by Segment–Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 57.** The US 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

## 15.CANADA

- A. Market Analysis
  - Current & Future Analysis
  - Product Launch
  - Strategic Corporate Developments
  - Focus on Select Major Players
- B. Market Analytics

**Table 58.** Canadian Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 59.** Canadian 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

## 16.JAPAN

- A. Market Analysis
  - Current & Future Analysis
  - Strategic Corporate Developments
  - Hitachi Medical Corporation – A Key Player
- B. Market Analytics

**Table 60.** Japanese Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 61.** Japanese 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and

Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

## 17.EUROPE

### A. Market Analysis

#### Current & Future Analysis

Biopharmaceutical Industry Tunes into Biomarker- Based Drug R&D

Biomarker Regulations in Europe

EMA's Experience in Pharmacogenetic Drugs - Still Nascent

Uncertain Laws Discourage VC Funding in Europe

Uncertainty Continues Among Regulators over Biomarker Validation Levels

### B. Market Analytics

**Table 62.** European Recent Past, Current and Future Analysis for Biomarkers by Geographic Region – France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 63.** European 10-Year Perspective for Biomarkers by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 64.** European Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnosics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 65.** European 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnosics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

## 17A.FRANCE

### A. Market Analysis

#### Current & Future Analysis

Strategic Corporate Development

BioMerieux (France) – A Key Player

### B. Market Analytics

**Table 66.** French Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnosics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 67.** French 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnosics and



Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

## 17B.GERMANY

- A. Market Analysis
  - Current & Future Analysis
  - Product Launches
  - Strategic Corporate Development
  - Epigenomics AG – A Key Player
- B. Market Analytics

**Table 68.** German Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnosics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 69.** German 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnosics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

## 17C.ITALY

- A. Market Analysis
  - Current & Future Analysis
  - Strategic Corporate Developments
- B. Market Analytics

**Table 70.** Italian Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnosics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 71.** Italian 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnosics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

## 17D.THE UNITED KINGDOM

- A. Market Analysis
  - Current & Future Analysis
  - Product Launches
  - Strategic Corporate Developments
  - Focus on Select Major Players
- B. Market Analytics

**Table 72.** The UK Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnosics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 73.** The UK 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnosics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

## 17E.REST OF EUROPE

- A. Market Analysis
  - Current & Future Analysis
  - Product Launches
  - Strategic Corporate Developments
  - Focus on Select Major Players
- B. Market Analytics

**Table 74.** Rest of European Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnosics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 75.** Rest of European 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnosics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

## 18.ASIA-PACIFIC

- A. Market Analysis
  - Current & Future Analysis
  - Product Launches
  - Strategic Corporate Developments
- B. Market Analytics

**Table 76.** Asia-Pacific Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnosics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 77.** Asia-Pacific 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnosics and Molecular Diagnostics) and Others] and Biomarker Servicesz [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

## 19.REST OF WORLD

### A. Market Analysis

Strategic Corporate Development

Compugen Ltd. (Israel)- A Key Player

### B. Market Analytics

**Table 78.** Rest of World Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnosics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)

**Table 79.** Rest of World 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnosics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

Total Companies Profiled: 204 (including Divisions/Subsidiaries - 210)

Region/CountryPlayers

The United States

Canada

Japan

Europe

France

Germany

The United Kingdom

Italy

Rest of Europe

Asia-Pacific (Excluding Japan)

Middle-East

### I would like to order:

**Product name:** Biomarkers: Market Research Report  
**Product link:** <http://marketpublishers.com/r/B0ACF7C2E29EN.html>  
**Product ID:** B0ACF7C2E29EN  
**Price:** US\$ 4,800.00 (Single User License / Electronic Delivery)

*If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [office@marketpublishers.com](mailto:office@marketpublishers.com)*

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <http://marketpublishers.com/r/B0ACF7C2E29EN.html>

### To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
E-mail:  
Company:  
Address:  
City:  
Zip/Post Code:  
Country:  
Tel:  
Fax:  
Your message:

\* All fields are required

Customer Signature \_\_\_\_\_

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at [http://marketpublishers.com/docs/terms\\_conditions.html](http://marketpublishers.com/docs/terms_conditions.html)

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**